Aptinyx to Present Preclinical Data on NYX-458 at the AD/PD 14th International Conference on Alzheimer’s & Parkinson’s Diseases
EVANSTON, Ill., March 22, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced upcoming presentations highlighting preclinical data on its novel NMDA receptor modulator, NYX-458, at the AD/PD 14th International Conference on Alzheimer’s & Parkinson’s Diseases in Lisbon, Portugal.
“We are excited to present these data, demonstrating the striking effects that NYX-458 has on cognitive impairment in a highly translatable non-human primate model of Parkinson’s disease,” said Cassia Cearley, Ph.D., vice president of research at Aptinyx. “Across the cognitive assessments used in the study, NYX-458 demonstrated rapid, robust, and enduring reversal of cognitive impairment. On some measures, cognitive performance was restored to healthy baseline levels. We are highly encouraged by these data and are working to advance NYX-458 in clinical development and toward patients that need better therapeutic options.”
Oral Presentation Details:
Presentation Title: The NMDAr modulator NYX-458 results in long-lasting improvement in several cognitive domains in a primate model of Parkinson’s disease cognitive impairment
Presenter: Cassia Cearley, Ph.D., Aptinyx
Time and Location: Friday, March 29th, 9:15am GMT, Auditorium V
Poster Presentation Details:
Presentation Title: The NMDAr modulator NYX-458 results in long-lasting improvement in several cognitive domains in a primate model of Parkinson’s disease cognitive impairment (Poster Number: 522)
Presenter: Cassia Cearley, Ph.D., Aptinyx
Poster Presentation: March 29th and March 30th
Presentation Title: The NMDAr modulator NYX-458 does not worsen motor symptoms or interfere with L-Dopa’s anti-parkinsonian effect in a non-human primate Parkinson’s disease model.
(Poster Number: 521)
Presenter: Cassia Cearley, Ph.D., Aptinyx
Poster Presentation: March 29th and March 30th
About NYX-458
NYX-458 is a novel, oral NMDA receptor modulator currently in Phase 1 clinical development for the treatment of cognitive impairment associated with Parkinson’s disease. In preclinical studies in rodents and non-human primates, NYX-458 has demonstrated rapid, robust, and enduring effects on cognitive impairment. A Phase 1 study evaluating the safety, tolerability, pharmacokinetics, and CNS exposure of NYX-458 is ongoing, and Aptinyx expects to report data from the study in the first half of 2019.
About Aptinyx
Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of proprietary synthetic small molecules for the treatment of brain and nervous system disorders. Aptinyx has a platform for discovery of novel compounds that work through a unique mechanism to modulate – rather than block or over-activate – NMDA receptors and enhance synaptic plasticity, the foundation of neural cell communication. The company has three product candidates in clinical development in central nervous system indications, including chronic pain, post-traumatic stress disorder, and cognitive impairment associated with Parkinson’s disease. Aptinyx is also advancing additional compounds from its proprietary discovery platform, which continues to generate a rich and diverse pipeline of small-molecule NMDA receptor modulators with the potential to treat an array of neurologic disorders. For more information, visit www.aptinyx.com.
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the company’s business plans and objectives, therapeutic effects of the company’s product candidates, expectations regarding the design, implementation, timing, and success of its current and planned clinical trials, expectations regarding its preclinical development activities, and expectations regarding its uses and sufficiency of capital. Risks that contribute to the uncertain nature of the forward-looking statements include: the success, cost, and timing of the company’s product candidate development activities and planned clinical studies; the company’s ability to execute on its strategy; regulatory developments in the United States and foreign countries; as well as those risks and uncertainties set forth in the company’s most recent annual report on Form 10-K and in its other filings and reports with the United States Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Aptinyx undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
Investor Contacts:
Nick Smith
Aptinyx Inc.
ir@aptinyx.com
847-871-0377
Rachel Frank
Stern Investor Relations
rachelf@sternir.com
212-362-1200
Media Contact:
Jordann Phillips
Canale Communications
jordann@canalecomm.com
619-849-6009
Source: Aptinyx Inc.
